Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
I remain confident that Synairgen are going to get good results in this trial. No point doing anything until the results come back.
As has been mentioned, we are not a test, we are medical intervention. If SN001 works this will multibag several times. A little patience needed while we wait on results. It is normal to see a retrace on the price during waiting period. We are actually doing very well considering the amount of people who sold to chase other stocks today. Some of those who left and made profit elsewhere will come back to drop profits here for a free ride.
I believe Synairgen can pull this off otherwise I would just sell and invest elsewhere
Yep, its the last story on BBC News https://www.bbc.co.uk/iplayer/live/bbcnews
PART 2 of email from NHS Glasgow & Clyde
....Graham Watson, Executive Chairman at SHIL adds: “Testing is a nuanced and technical area. However, an expert team has been mobilised at speed and we are now supporting a rapid, robust process to create a prototype, test against clinical samples; and if successful, progress through regulatory approval to manufacture. We are hoping to roll out the test within 12-15 weeks; but must remain cognisant that we are innovating at speed within a healthcare setting and with evolving scientific evidence.”
Accurate and reliable testing is a key pillar of the COVID-19 response strategy around the world and a key component of the safe and managed easing of current lockdown restrictions.
Notes:
Antibody tests for COVID-19 diagnosis fall into 2 groups
Antibody tests for diagnosis performed in laboratory on specialist equipment
Point of care antibody tests using a “lateral flow” mechanism
Lateral flow antibody tests require no specialist equipment and can be done anywhere, producing results in between 10 – 20minutes
Lateral flow antibody tests fall within the specification criteria for serology point of care tests and self-tests set out by Medicines and Healthcare products Regulatory Agency (MHRA). Target Product Profiles (TPP) have been developed to assist manufacturers to design and deliver tests that might be useful in support of Pillar 3 of the UK testing strategy. How closely a product matches the TPP will be helpful in procurement and regulatory decision making
To date, no such test has been validated and experts have urged people against purchasing unvalidated antibody (lateral flow) tests
The project brings together experts in the development of large scale test and antigen manufacture, clinicians, a major Scottish health board and an innovation development company
Project partners are: Scottish Health Innovations Limited (SHIL); NHS Greater Glasgow & Clyde, Excivion Limited, Lateral Dx Limited, Activotec Limited, The Antibody Company Limited, Axon Healthcare Investments Limited
The NHSGGC Biorepository is an invaluable resource for clinical research, providing access to a wide range of fully-consented human tissue samples including surplus materials from diagnostic and surgical procedures
ENDS
Rapid antibody test in development to support the fight against COVID-19
NHS Greater Glasgow and Clyde is collaborating on the development of an accurate and reliable antibody test in the fight against COVID-19.
With involvement of clinicians, the biorepository team and coordinated through Scottish Health Innovations Ltd; a UK-based consortium is accelerating the development of a unique lateral flow test, supporting the requirement for reliable antibody testing at scale.
Based on existing prototypes developed for Zika virus and Dengue fever and work on the herpes simplex virus; this innovative solution will be tested and validated using blood samples from previously infected COVID-19 patients.
Using a finger prick blood sample, the test will establish if a person has acquired antibodies to the COVID-19 virus. The presence of antibodies as markers of viral immunity is widely used in clinical practice to indicate exposure to a virus and a degree of immunity.
Using a novel and highly sensitive lateral flow (pregnancy-test-like) design, the diagnostic will use capillary blood samples, which can be extracted by a lancet from a fingertip in any point of care location. It will take around 20 minutes to complete, providing a reliable and accurate result.
Dr John Goodfellow – Consultant Neuroimmunologist and Clinical Director of the Neuroimmunology Laboratory at the Queen Elizabeth University Hospital, Glasgow explains: “There are two contexts in which testing is required - diagnosis of active infection, and diagnosis of likely immunity to infection. We are specifically looking at immunity to infection and our unique lateral flow design has several innovative features that will produce a more accurate test than traditional designs, and can be rapidly adapted to viral mutations. Our approach also, reduces the development time and manufacturing cost of the product.”
The project is being developed through a new company, Coronex Limited, that brings together the collaboration of NHS Greater Glasgow and Clyde, Scottish Health Innovations Ltd, UK based biotechnology industry partners and Glasgow-based investment partner Axon Healthcare.
The test will be developed and manufactured in the UK, ensuring secure, cost effective supply to the NHS. It addresses the urgent need for a diagnostic which demonstrates high sensitivity and accuracy, and at speed, whether a person has acquired immunity to the COVID-19 virus.
Professor Julie Brittenden, Research and Development Director at NHS Greater Glasgow and Clyde comments: “I am so proud of our team of clinicians, research nurses, biorepository specialists and patients who have made it possible to kick-start the development of a brand new antibody test for COVID-19. This is part of our wider research and development efforts to improve the diagnosis and treatment of the virus which includes clinical trials and innovative projects and the wider R&D Team.”
Graham Watson, Executive C
@TrustedInvestor haha agreed mate. Hoping to have a nice investing account for the kids when the hit 18. Growing the money is not the hard it. It's teaching the kids to invest and not blow it all on Booze & clothes lol
Price will tick back up. Today buys are again double sells. Buys 660k / Sells 352K
Yep, one more top up from me too. That's my last. Will just sit and wait now. I have a few of the Covid shares but I am invested in here marginally more than the others. When it comes to actually fighting the virus (or helping the body to, at least) this will be the first product to hit the market.
As Watching2 said. Our time will come. Lots of people bouncing around. Most went to ODX today. Just enjoy the fact that the Market gives you these opportunities to top up. News could land any day for Synairgen. They filled their trial slots in 1 week so I would say they are due to release results an day now.
This SP will go through the roof as soon as results confirmed.
Patience Patience Patience
Results will be any day now. They managed to get all recruits in >>1 week<<. Probably down to the fact that this drug is already established and tested to work on the lungs so people happy to join the trial.
"SG016, which looked at the effectiveness of a drug, SNG001, in improving lung function for patients with COVID-19, was able to finish recruitment within a week. Initial results from all trials are expected within weeks."
SOURCE: https://www [dot] uhb.nhs.uk/news/prioritising-covid-19-research.htm
Basically a repurposed sleep apnaa machine. This may put Bellescura even more in the picture. Hospital staff saying that they need to avoid putting people on ventilators as the odds of surviving are much reduced.
https://news.sky(dot)com/story/coronavirus-hospital-cuts-covid-19-death-rates-with-black-boxes-for-sleep-disorder-11977789
Well you don't see that very often. A full day with literally no pullback. So many people waiting to buy on the dip today and the dip just never came.
I think today's persistent rise shows excellent support and holders know they have a share worth £££ so do not get spooked into selling. Well done all holders.
GLA